Tackling the Opioid Crisis: Strategies to Improve Best Practices and Patient Outcomes

To access the activities, select a module title in the blue box above. Then, enter your name, email address, and degree in the appropriate fields of the form, and click Continue.

Jointly provided by Postgraduate Institute for Medicine and RME Collaborative.

Release Date: December 15, 2022

Expiration Date: December 15, 2023

Estimated Time to Complete: 15 minutes per module

PROGRAM OVERVIEW
In the United States, the leading cause of unintentional injury death is drug overdose, largely driven by opioid overdose. At the same time, millions of Americans are suffering from chronic pain, including high-impact pain that severely interferes with daily life and work activities. This CME/CE activity series aims to address this dual public health crisis by educating clinicians who treat and manage patients with pain through a series of short video modules. In each case-based video, Dr. Michael Brennan and Dr. Jeffrey Gudin will review various topics, including the fundamentals of pain, assessment of pain and risks, as well as treatment with pharmacologic (opioids and non-opioids) and non-pharmacologic modalities.

FACULTY
Michael J. Brennan, MD
Medical Director, Pain Center of Fairfield
Fairfield, CT
Senior Attending Physician, Department of Medicine, Physical Medicine, and Rehabilitation
Bridgeport Hospital
Bridgeport, CT

Jeffrey A. Gudin, MD
Professor of Anesthesiology, Perioperative Medicine, and Pain Management
University of Miami, Miller School of Medicine
Miami, FL

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.

LEARNING OBJECTIVES
Module 1: Fundamentals of Pain Management

Describe the fundamental concepts of pain management, including definitions and mechanisms of pain

Module 2: Assessment of Pain

Appropriately assess patients with pain and identify potential risk factors for abuse or addiction

Module 3: Weighing the Risks and Benefits of Opioid Therapy

Develop an individualized plan of care to safely initiate opioid treatment, while maximizing efficacy and minimizing risks

Module 4: Opioid Therapy for Acute and Chronic Pain

Review general and product-specific information about immediate-release (IR) and extended-release/long-acting (ER/LA) opioid analgesics

Module 5: Treatment of Chronic Persistent Pain

Describe the different therapeutic options for pain, including nonpharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies

Module 6: Managing and Monitoring Chronic Opioid Therapy

Utilize appropriate methods for monitoring patients using opioid therapy

Module 7: The Use & Misuse of Opioids: What Every Patient Should Know

Counsel patients about the safe use of opioids, safe disposal, potential for abuse and dependence, and overdose prevention (use of naloxone)

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 1: 0.25 AMA PRA Category 1 Credit™
Module 2: 0.25 AMA PRA Category 1 Credit™
Module 3: 0.25 AMA PRA Category 1 Credit™
Module 4: 0.25 AMA PRA Category 1 Credit™
Module 5: 0.25 AMA PRA Category 1 Credit™
Module 6: 0.25 AMA PRA Category 1 Credit™
Module 7: 0.25 AMA PRA Category 1 Credit™

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.4 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Module 1: 0.2 contact hour
Module 2: 0.2 contact hour
Module 3: 0.2 contact hour; 0.1 pharmacotherapy credit
Module 4: 0.2 contact hour; 0.1 pharmacotherapy credit
Module 5: 0.2 contact hour; 0.1 pharmacotherapy credit
Module 6: 0.2 contact hour; 0.1 pharmacotherapy credit
Module 7: 0.2 contact hour; 0.1 pharmacotherapy credit

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

Module 1: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-082-H08-P
Module 2: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-083-H08-P
Module 3: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-084-H08-P
Module 4: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-085-H08-P
Module 5: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-086-H08-P
Module 6: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-087-H08-P
Module 7: 0.25 contact hour (0.025 CEUs); UAN JA4008162-9999-23-088-H08-P

Type of Activity: Knowledge

HOW TO OBTAIN CREDIT
If you wish to receive CME/CE credits, please follow the below steps for each module you complete:

Listen to the entire activity.
Go to cmeuniversity.com. In the “Find Post-Test/Evaluation by Course” field at the top of the page, enter the course code 17822.
Select the module you completed and fill out the activity evaluation form. A certificate of participation will be available to download/print immediately.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Michael J. Brennan, MD, has disclosed the following relationships: speaker fees from BioDelivery Sciences International, Inc., RedHill Biopharma Ltd., and SCILEX Pharmaceuticals, Inc.

Jeffrey A. Gudin, MD, has disclosed the following relationships: consultant for Hisamitsu Pharmaceutical Co., Inc., Quest Diagnostics, and Sanofi; and grant/research support and ownership interest in Virpax Pharmaceuticals.

Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS educational requirements issued by the US Food and Drug Administration.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CONTACT US
General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine via email at inquiries@pimed.com.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer 11, Microsoft Edge, Firefox 27+, Chrome 30+, Safari 9+
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable